Skip to Content
Merck
All Photos(3)

Key Documents

PLA0185

Sigma-Aldrich

Rabbit anti-BRCA1 Antibody, Affinity Purified

Powered by Bethyl Laboratories, Inc.

Synonym(s):

BRCA1/BRCA2-containing complex, BRCAI, BRCC1, BROVCA1, FANCS, Fanconi anemia, IRIS, PNCA4, PPP1R53, PSCP, RING finger protein 53, RNF53, breast and ovarian cancer susceptibility protein 1, breast and ovarian cancer sususceptibility protein 1, breast cancer 1, complementation group S, early onset, early onset breast cancer 1, protein phosphatase 1, regulatory subunit 53, subunit 1, truncated BRCA1, truncated breast and ovarian cancer susceptibility protein 1, truncated breast and ovarian cancer sususceptibility protein 1, truncated breast cancer type 1 susceptibility protein

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

Quality Level

100

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

grade

Powered by Bethyl Laboratories, Inc.

species reactivity

human

concentration

1 mg/mL

technique(s)

immunohistochemistry: 1:500- 1:2,000
immunoprecipitation (IP): 2-10 μg/mg
western blot: 1:500- 1:2,500

accession no.

NP_009225.1

UniProt accession no.

P38398

shipped in

wet ice

storage temp.

2-8°C

target post-translational modification

unmodified

Gene Information

rabbit ... BRCA1(672)

Related Categories

Immunogen

The epitope recognized by PLA0185 maps to a region between residue 250 and 300 of human breast cancer 1 using the numbering given in entry NP_009225.1 (GeneID 672).

Physical form

Tris-citrate/phosphate buffer, pH 7 to 8 containing 0.09% Sodium Azide

Other Notes

BRCA1 was identified as a gene with germline mutations that predisposes women to breast and ovarian cancer. The BRCA1 tumor suppressor is a large protein that has been demonstrated to interact with a multitude of proteins involved in the DNA damage response and cell cycle checkpoints to maintain genomic integrity. BRCA1 functions by regulating the activities of its interacting proteins which mediate processes such as gene transcription, gene repression, protein phosphorylation, and ubiquitination.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Feng Bai et al.
Cancer research, 74(21), 6161-6172 (2014-09-23)
BRCA1 mutation carriers are predisposed to developing basal-like breast cancers with high metastasis and poor prognosis. Yet, how BRCA1 suppresses formation of basal-like breast cancers is still obscure. Deletion of p18(Ink4c) (p18), an inhibitor of CDK4 and CDK6, functionally inactivates
Bárbara Alcaraz Silva et al.
The Journal of biological chemistry, 289(33), 22771-22784 (2014-07-02)
Chromosome ends contain nucleoprotein structures known as telomeres. Damage to chromosome ends during interphase elicits a DNA damage response (DDR) resulting in cell cycle arrest. However, little is known regarding the signaling from damaged chromosome ends (designated here as "TIPs")
Qing Xia et al.
International journal of oncology, 44(3), 735-744 (2014-01-01)
Breast cancer is one of the most common malignancies in women. Approximately 15% of the patients belong to the triple-negative breast cancer (TNBC) group, and have the disadvantage of not benefiting from currently available receptor-targeted systemic therapies. Some cancers in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service